Megan is a seasoned freelance writer with a passion for delving into the intricacies of parenthood. Throughout her five-plus years of crafting insightful content, Megan has drawn from her firsthand ...

A vaccine Moderna has long been developing for the world’s most common congenital infection has failed a Phase 3 trial. The biotechnology company said late Wednesday that the shot, dubbed mRNA-1647, ...

Moderna's decision not to diversify outside of COVID has hurt its business substantially. The company is still generating COVID revenue, but it's insufficient to cover its operating expenses. It's ...

Moderna Inc. (NASDAQ:MRNA) announced on Sunday that its clinical, safety, and translational data from its Phase 1/2 study evaluating mRNA-4359 in combination with ...

Moderna has shared some of the phase 1/2 data that persuaded it to expand and prioritize development of a cancer candidate, reporting responses in melanoma patients failed by checkpoint inhibitors.

Moderna’s mRNA-4359, when used with Keytruda, achieves a 24% overall objective response rate in patients with melanoma, with efficacy increasing to 67% in those positive for PD-L1. Moderna’s ...

Moderna (MRNA) announced that clinical, safety and translational data from its Phase 1/2 study evaluating mRNA-4359 in combination with pembrolizumab in checkpoint ...

While each product featured is independently selected by our editors, we may include paid promotion. If you buy something through our links, we may earn commission. Read more about our Product Review ...

Moderna has early in-human data showing its next-generation COVID-19 vaccine, mNEXSPIKE, has the potential to offer strong immune protection against the latest rapidly spreading SARS-CoV-2 virus.

Moderna said on Tuesday its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and older, as well as in individuals aged 12 to 64 with at least one underlying ...

Moderna (NASDAQ:MRNA) has agreed to resolve a patent litigation in which Alnylam Pharmaceuticals (NASDAQ:ALNY) has alleged that the delivery technology used in the company’s COVID-19 vaccine has ...